Loading...
Protein-based nanoparticles for antimicrobial and cancer therapy: implications for public health
Ifijen, Ikhazuagbe H. Awoyemi, Raymond Femi Faderin, Emmanuel Akobundu, Uchenna U. Ajayi, Abiola S. Chukwu, Janefrances U. Lekan, Ogunnaike K. Asiriuwa, Olutoyin D. Maliki, Muniratu Ikhuoria, Esther U.
Ifijen, Ikhazuagbe H.
Awoyemi, Raymond Femi
Faderin, Emmanuel
Akobundu, Uchenna U.
Ajayi, Abiola S.
Chukwu, Janefrances U.
Lekan, Ogunnaike K.
Asiriuwa, Olutoyin D.
Maliki, Muniratu
Ikhuoria, Esther U.
Citations
Altmetric:
Files
Other Names
Location
Time Period
Advisors
Original Date
Digitization Date
Issue Date
2025-05-08
Type
Review
Genre
Keywords
Subjects (LCSH)
Citation
Ifijen, Ikhazuagbe & Awoyemi, Raymond & Faderin, Emmanuel & Akobundu, Uchenna & Ajayi, Abiola & Chukwu, Janefrances & Lekan, Ogunnaike & Asiriuwa, Olutoyin & Maliki, Muniratu & Ikhuoria, Esther. (2025). Protein-based nanoparticles for antimicrobial and cancer therapy: implications for public health. RSC Advances. 15. 14966-15016. 10.1039/D5RA01427A.
Abstract
This review discusses the growing potential of protein-based nanoparticles (PBNPs) in antimicrobial and cancer therapies, emphasizing their mechanisms of action, applications, and future prospects. In antimicrobial therapy, PBNPs exhibit several mechanisms of action, including disruption of microbial membranes, enhanced antibiotic delivery, immune modulation, and biofilm disruption. Protein nanoparticles like albumin, lactoferrin, gelatin, and peptide-based variants enhance the efficacy of antibiotics, offering targeted approaches to combat multidrug-resistant pathogens. Their ability to improve drug localization and enhance microbial eradication represents a significant advancement in infectious disease management. In cancer therapy, PBNPs facilitate targeted drug delivery, controlled release, tumor microenvironment modulation, and photothermal and photodynamic therapies. Nanoparticles such as Abraxane® and engineered ferritin nanocages are at the forefront of cancer treatment, enhancing the precision and effectiveness of chemotherapy while minimizing adverse effects. Additionally, silk fibroin nanoparticles are being explored for their biodegradability and targeting capabilities. Despite their promise, challenges remain, including the scalability of production, long-term safety concerns, regulatory approval processes, and environmental impact. Addressing these issues through rigorous research and innovation is crucial for integrating PBNPs into mainstream therapeutic practices. PBNPs offer transformative solutions in both antimicrobial and cancer therapies, with significant implications for improving public health outcomes globally. © 2025 The Royal Society of Chemistry.
Table of Contents
Description
This is an open access article under the CC BY license.
Publisher
Royal Society of Chemistry
Journal
RSC Advances
Book Title
Series
Digital Collection
Finding Aid URL
Use and Reproduction
Archival Collection
PubMed ID
ISSN
20462069